中国人群早孕期子痫前期筛查策略的前瞻性评估及其临床适用性
结果显示,在10%、15%、20%固定假阳性率下,三联标志物模型对早产子痫前期的检出率分别为65.0%、72.7%、76.1%;筛查阳性者发生其他胎盘相关不良妊娠结局的风险增加。
要点
- FMF竞争风险模型在中国大陆人群中对早产子痫前期筛查有效。
- MAP、UtA-PI和PAPP-A三联模型在10%假阳性率下检出65.0%早产子痫前期。
- 早产子痫前期筛查阳性者其他胎盘相关不良结局风险增加。
核心结论
- FMF竞争风险模型在中国大陆人群中对早产子痫前期筛查有效。
- 筛查阳性孕妇发生其他胎盘相关妊娠并发症的风险增加。
研究设计与样本
- 于孕11+0至13+6周测量MAP、UtA-PI、PAPP-A和PlGF,并转换为中国参考范围的中位数倍数。
- 采用FMF算法计算早产子痫前期个体化风险,并评估不同标志物组合的筛查效率。
诊断标准与关键数值
- 在10%、15%、20%固定假阳性率下,MAP+UtA-PI+PAPP-A三联模型对早产子痫前期的检出率分别为65.0%、72.7%、76.1%。
- 相同假阳性率下,该模型对严重复合胎盘相关不良结局的检出率分别为34.7%、41.7%、46.4%。
- 以PAPP-A替换为PlGF或在模型中添加PlGF未改善筛查性能。
- 在5%固定假阳性率下筛查阳性孕妇中,约30%发生至少一种胎盘相关不良妊娠结局。
临床应用与阅片要点
- 可在中国大陆早孕期人群中应用FMF竞争风险模型进行早产子痫前期筛查。
- 筛查阳性者应关注其他胎盘相关不良妊娠结局的风险。
- 联合MAP、UtA-PI和PAPP-A是有效的筛查标志物组合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate, in a Chinese population, the performance of a screening strategy for preterm pre-eclampsia (PE) using The Fetal Medicine Foundation (FMF)'s competing-risks model and to explore its clinical applicability in mainland China.
METHODS: This was a prospective, multicenter, observational cohort study including 10 899 women with singleton pregnancy who sought prenatal care at one of 13 hospitals, located in seven cities in mainland China, between 1 December 2017 and 30 December 2019. Mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and maternal serum levels of placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A) at 11 + 0 to 13 + 6 weeks' gestation were measured and converted into multiples of the median using Chinese reference ranges. Individualized risk for preterm PE was calculated using the FMF algorithm. Prior risk was calculated based on maternal demographic characteristics and obstetric history. We evaluated the efficiency of the screening strategy using various combinations of biomarkers and analyzed its predictive performance for a composite of placenta-associated adverse pregnancy outcomes, including PE, placental abruption, small-for-gestational age (SGA) and preterm birth, at fixed false-positive rates for preterm PE.
RESULTS: We identified 312 pregnancies that developed PE, of which 117 cases were diagnosed as preterm PE (< 37 weeks' gestation). There were 386 pregnancies complicated by severe composite placenta-associated adverse outcome, including preterm PE, 146 cases of severe SGA (birth weight < 3rd percentile) neonate, 61 cases with placental abruption and 109 cases of early preterm birth < 34 gestational weeks. The triple-marker model containing biomarkers MAP, UtA-PI and PAPP-A achieved, at fixed false-positive rates of 10%, 15% and 20%, detection rates for preterm PE of 65.0%, 72.7% and 76.1%, respectively, and detection rates for severe composite placenta-associated adverse outcome of 34.7%, 41.7% and 46.4%, respectively. Replacing PAPP-A with PlGF or adding PlGF to the model did not improve the performance. Of women screening positive for preterm PE at a fixed 5% false-positive rate, an estimated 30% developed at least one placenta-associated adverse pregnancy outcome, including PE, placental abruption, SGA (birth weight < 10th percentile) and preterm birth < 37 weeks.
CONCLUSIONS: The FMF competing-risks model for preterm PE was found to be effective in screening a mainland Chinese population. Women who screened positive for preterm PE had increased risk for other placenta-associated pregnancy complications. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Hu J, Gao J, Liu J, et al. Prospective evaluation of first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China. Ultrasound Obstet Gynecol. 2021. PMID: 33817865. doi:10.1002/uog.23645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。